THE ELMEZZI GRADUATE SCHOOL OF MOLECULAR MED
AI Summary
The Elmezzi Graduate School of Molecular Medicine is a nonprofit organization dedicated to advancing medical education and university education. With an operating budget of $1.3 million and total revenue of $1.9 thousand for the filing year 2024, the organization focuses on providing high-quality education in the field of molecular medicine. More information about its programs and initiatives can be found on its website at www.northwell.edu.
Was this helpful?
This summary is AI-generated from ChatGPT. It’s meant to be helpful, but isn’t always perfect.
Mission Statement
EDUCATION
Cause Areas
2
University education
Medical education
Explore this org's ecosystem
See similar nonprofits by cause and location, their funders, and their grants.
Learn about Ecosystems


Explore this org's ecosystem
See similar nonprofits by cause and location, their funders, and their grants.
Learn about Ecosystems
Charity Verification Snapshot
IRS EO Business Master File Status
Listed as tax-exempt
IRS Pub 78 Status
Eligible for tax-deductible gifts
IRS Revocation Status
Not in Automatic Revocation of Exemption List
Go beyond basic verification
Instantly get 50+ financial health and governance metrics, including LUNA.
Learn about Due Diligence


Go beyond basic verification
Instantly get 50+ financial health and governance metrics, including LUNA.
Learn about Due Diligence
Frequently Asked Questions
What is THE ELMEZZI GRADUATE SCHOOL OF MOLECULAR MED’s budget?
In 2024, THE ELMEZZI GRADUATE SCHOOL OF MOLECULAR MED reported an annual operating budget of around $1.3 million. More detailed financial information is available to registered users.
What causes does THE ELMEZZI GRADUATE SCHOOL OF MOLECULAR MED support?
THE ELMEZZI GRADUATE SCHOOL OF MOLECULAR MED supports work in University education and Medical education.
Where does THE ELMEZZI GRADUATE SCHOOL OF MOLECULAR MED operate?
THE ELMEZZI GRADUATE SCHOOL OF MOLECULAR MED is headquartered in Westbury, NY.
Copyright 2026. All rights reserved to Chario Inc. (d.b.a. Impala)